Glomerulus (kidney)

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

Retrieved on: 
Thursday, May 19, 2022

Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.

Key Points: 
  • Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
  • As of the May 6, 2022 data cutoff, BION-1301 has been well-tolerated, with no serious adverse events or treatment discontinuations due to adverse events.
  • BION-1301 durably reduced serum IgA and IgM levels, and to a lesser extent, IgG levels in all patients.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.